tldrdailynews.com logo

Bristol Myers Stock Climbs After Strong Q2 Beat and Raised Guidance

1 min read
Source: Barron's
Bristol Myers Stock Climbs After Strong Q2 Beat and Raised Guidance
Photo: Barron's
TL;DR Summary

Bristol Myers Squibb beat expectations on second-quarter adjusted earnings and revenue and lifted its full-year guidance to $49–$50 billion as newer therapies offset declines in legacy drugs; Eliquis grew 21% to $4.48 billion, contributing to the beat and helping lift the stock.

Topics:business#bristol-myers-squibb#earnings#earnings-guidance#eliquis#markets#opdivo
Share this article
  1. Bristol Myers Stock Rises After Beating Earnings Expectations and Hiking Guidance  Barron's
  2. BMS pushes key readouts for Cobenfy, milvexian to 2027  FirstWord Pharma
  3. Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales  finance.yahoo.com
  4. Bristol Myers Lifts Outlook as Profit, Revenue Rise  WSJ
  5. Bristol Myers Squibb raises 2026 forecast after Q2 earnings beat  qz.com

Reading Insights

Total Reads

1

Unique Readers

4

Time Saved

17 min

vs 17 min read

Condensed

99%

3,383 → 42 words

Want the full story? Read the original article

Read on Barron's